Hims & Hers Health Inc [HIMS] stock prices are up 31.02% to $13.43 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HIMS shares have gain 39.75% over the last week, with a monthly amount glided 52.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Revenue of $872.0 million, up 65% year-over-year in 2023.
From an analyst’s perspective:
Hims & Hers Health Inc [NYSE: HIMS] stock has seen the most recent analyst activity on February 26, 2024, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $10. Previously, Imperial Capital started tracking the stock with In-line rating on December 07, 2023, and set its price target to $9. On July 28, 2023, TD Cowen initiated with a Outperform rating and assigned a price target of $11 on the stock. Robert W. Baird started tracking the stock assigning a Neutral rating and suggested a price target of $10 on April 11, 2023. Jefferies upgraded its rating to a Buy and raised its price target to $11 on February 09, 2023. SVB Leerink upgraded its rating to Outperform for this stock on November 08, 2022, but kept the price target unchanged to $5. In a note dated November 08, 2022, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $7.50 to $8.50.
The stock price of Hims & Hers Health Inc [HIMS] has been fluctuating between $5.65 and $12.34 over the past year. Currently, Wall Street analysts expect the stock to reach $6.33 within the next 12 months. Hims & Hers Health Inc [NYSE: HIMS] shares were valued at $13.43 at the most recent close of the market. An investor can expect a potential drop of -52.87% based on the average HIMS price forecast.
Analyzing the HIMS fundamentals
The Hims & Hers Health Inc [NYSE:HIMS] reported sales of 872.00M for trailing twelve months, representing a surge of 47.50%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.90 points at the first support level, and at 10.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.44, and for the 2nd resistance point, it is at 15.44.
Hims & Hers Health Inc [HIMS] reported earnings per share of $0.01 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.02/share, meaning a difference of $0.03 and a surprise factor of 150.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.04 per share as compared to estimates of -$0.03 per share, a difference of -$0.01 representing a surprise of -33.30%.
Ratios To Look Out For
It’s worth pointing out that Hims & Hers Health Inc [NYSE:HIMS]’s Current Ratio is 3.00. In addition, the Quick Ratio stands at 2.74 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 3.26, the price to book ratio is 8.33.
Transactions by insiders
Recent insider trading involved Boughton Soleil, Chief Legal Officer, that happened on Feb 15 when 5972.0 shares were sold. Chief Executive Officer, Dudum Andrew completed a deal on Feb 14 to sell 77382.0 shares. Meanwhile, Chief Legal Officer Boughton Soleil sold 17109.0 shares on Feb 14.
